ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGY Allergy Therapeutics Plc

3.00
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.80 3.20 3.00 3.00 3.00 32,599 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.33 142.99M
Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 3p. Over the last year, Allergy Therapeutics shares have traded in a share price range of 0.85p to 3.80p.

Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £142.99 million. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -3.33.

Allergy Therapeutics Share Discussion Threads

Showing 2926 to 2947 of 5000 messages
Chat Pages: Latest  128  127  126  125  124  123  122  121  120  119  118  117  Older
DateSubjectAuthorDiscuss
04/11/2014
07:23
Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Appointment of Dr Daphne Tsitoura as Head of Clinical Science
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10th November, reporting to Professor Tim Higgenbottam.

Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York.

Tim Higenbottam, R & D Director said:

"With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US."

jimmyloser
04/11/2014
07:13
Well its certainly an interesting appointment. However, I can't help but think its in response to the last couple of years impasse especially in the US where little appears to have happened since the clinical trial hold was lifted. Hopefully this will drive things forward. but you have to wonder at what pace? Still lots of potential here but they need to crack-on and deliver before somebody else beats them to it
audigger
27/10/2014
07:49
I find the note to editors interesting with its recently changed wording.

Note the use of the words and context of 'infrastructure' and 'distributors' and how expansion into emerging markets (USA?) is with 'infrastructure' and not 'distributors'!

impo/dyor

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

jimmyloser
23/10/2014
15:48
Interesting little jump today!
audigger
16/10/2014
16:13
Seems to be a familiar pattern with AGY.
audigger
16/10/2014
09:59
Hardly "glowing int he dark" at the moment eh Cube.Slightly disappointing downward motion.
algernon2
07/10/2014
15:33
Cube,
I agree. It was interesting that they only issued positive noises on the USA though.

How do you view the presence of Abbott on the scene?

jimmyloser
07/10/2014
13:10
Back to normal! no news with results and down we go!.
Need the US deal or the same pattern every 6 months..GLA ;0))

cube boss
06/10/2014
07:12
Not long for Allergy as we know it Jim??
jimmyloser
02/10/2014
17:16
No problem with that, but why drop reference to the GBP45.7 million figure? Of course, a higher figure would be good,.
farmer george
02/10/2014
16:46
It means that they are signalling that they are ramping up in the USA as I read it.

I am not ramping up though. lol,

Patience as the Cube would say.

jimmyloser
02/10/2014
16:27
...does that mean the earlier cited number of GBP45.7 million will be under-shot or, indeed, exceeded? We wait.
farmer george
02/10/2014
14:54
The Company is expanding its infrastructure into the Emerging Markets.
jimmyloser
02/10/2014
14:52
Hmmmm...no forecast for 2014?
farmer george
02/10/2014
14:34
This was September 4th 2014

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with expected revenue of GBP45.7million, before milestones and rebates and supported by a foreign exchange benefit of GBP2.3million, an increase of 14% on the previous year (2013:GBP39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This was this week - spot the important difference

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost GBP40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

jimmyloser
01/10/2014
14:50
It will be very interesting to see if these loose shares are mopped up later!
jimmyloser
30/9/2014
20:30
Manuel Llobet said


"creating value for ......'all'..... our shareholders."

jimmyloser
30/9/2014
08:24
That's what I thought, it's unlikely now that they'll be enough stock out there to send the price up and those that have the stock can influence the price with timing of events etc. Could it now be that the stock we're sat on doesn't amount to sufficient for them to worry about? Will they want to claw back all the stock before investing in the future or announcing the future?
aruntim
30/9/2014
07:58
THIS IS PURE CONJECTURE ON MY PART.

It appears that Allergy now have a major new shareholder in Abbott. It's my guess and a guess only that it is Abbott who are keeping our share price where it is and are picking up every share that they can get their hands on at best price.

Is it a poison chalice for Allergy and for us this takeover of CFR?.

I personally cant see any independent future now for Allergy. Their future looks to be part of a bigger group.

No prizes for guessing which group!

40p per share by Christmas.

impo/pure conjecture/dyor etc etc

jimmyloser
30/9/2014
07:47
What's happened now, any chance of a Twitter style 140 character summary?
aruntim
25/9/2014
16:34
Every single share IS wanted....

I rest my case.


100,000 @ 24.625

You sell 'em and they will buy them.

A brilliant report earlier this week.

impo

jimmyloser
25/9/2014
07:46
More late 75K trades yday. Looks like they were both sells hence the drop this am. I think we may see a small pull back and then a jumpt back to 30. Time will tell!
audigger
Chat Pages: Latest  128  127  126  125  124  123  122  121  120  119  118  117  Older

Your Recent History

Delayed Upgrade Clock